Macrogenics (MGNX)

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

O preço da ação MacroGenics, Inc. Common Stock (MGNX) after-hours hoje é de , refletindo uma movimentação de NaN% after-hours desde que o mercado fechou. A capitalização de mercado da empresa é de $ 122,72 mi, com um volume comercial diário de  ações. O preço de fechamento anterior foi .

Vamos começar? Siga os passos abaixo ou leia nosso guia sobre como comprar Macrogenics ações na Kraken a partir de US$ 10.